Gareth Peter Gregory
Fiona Stanley Hospital · 193 works · 3,240 citations · h-index 28
Top works
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
- Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
- CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- Rituximab is associated with improved survival for aggressive B cell CNS lymphoma
- Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
- Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
- Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma
- Failure of eculizumab to correct paroxysmal cold hemoglobinuria
- BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
- Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID ‐19 pandemic
- High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
- Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas
- Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
- Prevention and management of obinutuzumab‐associated toxicities: Australian experience
- Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis